<DOC>
	<DOC>NCT00269217</DOC>
	<brief_summary>This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6 scheduled clinic visits, and 7 treatment arms.</brief_summary>
	<brief_title>Lipid Efficacy Study (0524B-022)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type V</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patients 18 to 85 years of age with primary hypercholesterolemia or mixed hyperlipidemia LDLC between 130 and 190 mg/L (Category I) and 130 and 160 mg/L (Category II) and triglycerides &lt;/= 350 mg/dL. A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study Patients with &lt;80% compliance Patients with certain medical conditions Patients taking certain concomitant medications and/or with unstable doses of medications Or those with a history of CHD/CHD equivalent or diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>